Search Results - "Inada, Ken"

Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia".

Authors: Inada, Ken Fukumoto, Kentaro Hasegawa, Naomi et al.

Source: Neuropsychopharmacology Reports. Dec2022, Vol. 42 Issue 4, p502-509. 8p.

Comparison of Efficacies of a Blonanserin Transdermal Patch and Blonanserin Oral Formulation for Psychiatric Symptoms in Patients With Schizophrenia Treated With Laxatives Using a Japanese Claims Database.

Authors: Inada, Ken Muraoka, Hiroyuki Matsumoto, Yuji et al.

Source: Neuropsychopharmacology Reports. Mar2025, Vol. 45 Issue 1, p1-7. 7p.

Eight‐Year Progression of Clinical Practice Implementation Following Guideline Training in the EGUIDE Project.

Authors: Ide, Kenta Yamamuro, Kazuhiko Yamada, Hisashi et al.

Source: Neuropsychopharmacology Reports. Mar2026, Vol. 46 Issue 1, p1-7. 7p.

Management of unspecified anxiety disorder: Expert consensus.

Authors: Sakurai, Hitoshi Inada, Ken Aoki, Yumi et al.

Source: Neuropsychopharmacology Reports. Jun2023, Vol. 43 Issue 2, p188-194. 7p.

Long‐Term Impact of EGUIDE Training on Facility‐Wide Guideline Adherence Rate in Schizophrenia and Major Depressive Disorder: A Multicenter Study.

Authors: Hasegawa, Naomi Muraoka, Hiroyuki Arai, Yusuke et al.

Source: Neuropsychopharmacology Reports. Dec2025, Vol. 45 Issue 4, p1-8. 8p.

Factors associated with death, hospitalization, resignation, and sick leave from work among patients with schizophrenia in Japan: a nested case–control study using a large claims database.

Authors: Inada, Ken Saito, Yoshitaka Baba, Kenji et al.

Source: BMC Psychiatry. 1/3/2024, Vol. 24 Issue 1, p1-8. 8p.

Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study.

Authors: Ishigooka, Jun Nakagome, Kazuyuki Ohmori, Tetsuro et al.

Source: Psychiatry & Clinical Neurosciences. Jan2022, Vol. 76 Issue 1, p22-31. 10p. 1 Diagram, 3 Charts, 1 Graph.

Subjects: Social skills, People with schizophrenia, Antipsychotic agents, Termination of treatment, Aripiprazole

Geographic Terms: Japan

A 12-Week, Open-Label, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Lemborexant in Patients with Insomnia Comorbid with Depressive Episodes (SELENADE).

Authors: Takaesu, Yoshikazu Muraoka, Hiroyuki Takeshima, Masahiro et al.

Source: CNS Drugs. Mar2026, Vol. 40 Issue 3, p467-480.

Author Index.

Source: Pathology International. Dec2004, Vol. 54 Issue 12, p936-941. 6p.

Author Index.

Source: Pathology International. Dec2018, Vol. 68 Issue 12, p719-723. 5p.

Current state of hypnotic use disorders: Results of a survey using the Japanese version of Benzodiazepine Dependence Self‐Report Questionnaire.

Authors: Yamamoto, Mai Inada, Ken Enomoto, Minori et al.

Source: Neuropsychopharmacology Reports. Mar2021, Vol. 41 Issue 1, p14-25. 12p.

Psychometric Properties of the Drug Stigma Scale Among Community Pharmacists Concerning Individuals Who Use Over‐The‐Counter Drugs.

Authors: Katayama, Munenori Shimane, Takuya Shirakawa, Norihito et al.

Source: Neuropsychopharmacology Reports. Mar2026, Vol. 46 Issue 1, p1-8. 8p.

Clinical practice for unspecified anxiety disorder in primary care.

Authors: Sakurai, Hitoshi Takeshima, Masahiro Inada, Ken et al.

Source: Psychiatry & Clinical Neurosciences Reports. Sep2023, Vol. 2 Issue 3, p1-7. 7p.

Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study.

Authors: Ishigooka, Jun Inada, Ken Niidome, Kazunari et al.

Source: Human Psychopharmacology: Clinical & Experimental. Jul2021, Vol. 36 Issue 4, p1-9. 9p.

Subjects: People with schizophrenia, Japanese people, Blood sugar, Dopamine antagonists, Weight gain, Dopamine receptors

Author Index.

Source: Pathology International. Dec2005, Vol. 55 Issue 12, p810-814. 5p.

Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and meta‐analysis.

Authors: Takeshima, Masahiro Otsubo, Tempei Funada, Daisuke et al.

Source: Psychiatry & Clinical Neurosciences. Apr2021, Vol. 75 Issue 4, p119-127. 9p. 6 Diagrams, 3 Charts, 1 Graph.

Subjects: Cognitive therapy, Anxiety disorders, Benzodiazepines, Drug efficacy, Anxiety treatment, Catatonia

Patterns of hypnotic prescribing for residual insomnia and recurrence of major depressive disorder: a retrospective cohort study using a Japanese health insurance claims database.

Authors: Yamato, Kentaro Inada, Ken Enomoto, Minori et al.

Source: BMC Psychiatry. 1/13/2021, Vol. 21 Issue 1, p1-12. 12p. 2 Diagrams, 2 Charts, 1 Graph.

Clozapine‐induced agranulocytosis in Japan: Changes in leukocyte/neutrophil counts before and after discontinuation of clozapine.

Authors: Matsui, Kentaro Ishibashi, Mikiko Kawano, Masahiko et al.

Source: Human Psychopharmacology: Clinical & Experimental. Jul2020, Vol. 35 Issue 4, p1-8. 8p.

Subjects: Agranulocytosis, Leukocyte count, Leukocytes, Patient monitoring, Neutropenia

Geographic Terms: Japan

The impact of the number of non-opioid psychotropic medications and their co-exposures during pregnancy on short-term outcomes in full-term neonates.

Authors: Isohata, Hitoshi Miura, Sumie Yamazaki, Yu et al.

Source: Scientific Reports. 8/22/2025, Vol. 15 Issue 1, p1-9. 9p.

Role of Serum Lithium Concentrations in Predicting Hyperparathyroidism and Hypercalcemia.

Authors: Takano, Noriyoshi Morimoto, Satoshi Muraoka, Hiroyuki et al.

Source: International Journal of Endocrinology. 7/24/2025, Vol. 2025, p1-7. 7p.